Nxstage Medical (NAS: NXTM) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Nxstage Medical met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded. GAAP loss per share shrank.
Gross margins grew, operating margins contracted, net margins expanded.
Nxstage Medical chalked up revenue of $61.6 million. The nine analysts polled by S&P Capital IQ wanted to see revenue of $61.1 million on the same basis. GAAP reported sales were 8.2% higher than the prior-year quarter's $57.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.08. The eight earnings estimates compiled by S&P Capital IQ predicted -$0.08 per share. GAAP EPS were -$0.08 for Q1 versus -$0.09 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 38.9%, 150 basis points better than the prior-year quarter. Operating margin was -7.4%, 100 basis points worse than the prior-year quarter. Net margin was -8.1%, 90 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $64.2 million. On the bottom line, the average EPS estimate is -$0.07.
Next year's average estimate for revenue is $264.4 million. The average EPS estimate is -$0.28.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 140 members out of 171 rating the stock outperform, and 31 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Nxstage Medical a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $16.59.
Is Nxstage Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
Add Nxstage Medical to My Watchlist.
The article Nxstage Medical Beats Up on Analysts Yet Again originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends NxStage Medical. The Motley Fool owns shares of NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.